DZP has advised Guggenheim Securities, LLC, sole placement agent in the USA, in a private offering of shares in Mabion S.A.

Mabion S.A. raised financing of PLN 174.8 million by the Company’s shareholder, i.e. Twiti Investments Ltd., selling shares representing 16% of the Company’s share capital and 14.37% of total votes in the Company in a private offering and transferring the proceeds to the Company under a loan agreement.

Institutional investors focused on the healthcare and life sciences sector, e.g. from the USA, took part in the offering, which has led to the strengthening and diversification of the Mabion shareholder base, as did the European Bank for Reconstruction and Development and Polish Development Fund Life Science sp. z o.o., belonging to the Polish Development Fund.

Mabion S.A. is the first Polish biotech company and the only one in Poland to number among its achievements innovations in developing and implementing a new generation of biotech drugs based on monoclonal antibody technology, which today is a foundation for combating the most serious diseases thanks to two exceptional features – specificity and safety. The medicines developed by the Company are targeted therapies, characterised by their ability to recognise and impact only carcinogens.

Guggenheim Securities is the investment banking business of Guggenheim Partners, a company employing over 2,500 people around the world, based in Chicago and New York. Over the past ten years Guggenheim Securities has advised on transactions worth over a billion dollars. In addition to investment banking services, Guggenheim Partners offers investment management and advisory services. The CEO of Guggenheim Partners is also a trustee of the Solomon R. Guggenheim Foundation, a globally renowned non-profit organisation that collects, preserves, and interprets modern and contemporary art.

The project was led by Tomasz Kalicki from the Capital Markets and Financial Institutions Practice. Magdalena Skowrońska also advised on the transaction.